Investor Presentaiton

9MFY24 financial highlights Particulars Revenue from operations Other income Reported revenue Material costs 9M FY24 9M FY23 YoY change 25,717 21,985 17% 745 481 55% 26,462 22,466 18% 7,274 5,664 28% Staff costs 7,105 6,347 12% Other direct costs 805 835 -4% Other expenses 3,100 2,561 21% Foreign exchange (gain)/loss, net 458 376 22% EBITDA 7,720 6,682 16% EBITDA Margin 29% 30% Depreciation and Finance Cost 3,491 3,055 14% PBT 4,229 3,627 17% Tax 930 771 21% PAT before exceptional items 3,299 2,856 16% PAT Margin 12% 13% PAT after exceptional items* 3,214 2,856 13% All figures in Rs. Mn unless otherwise specified Syngene *(Exceptional item (net of tax) in FY24 pertains to transaction costs relating to the acquisition of multi modal facility (Unit 3) of Stelis Biopharma Limited (SBL) Putting Science to Work 29

View entire presentation